Compare LMB & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMB | MGTX |
|---|---|---|
| Founded | 1901 | 2015 |
| Country | United States | United States |
| Employees | 1400 | N/A |
| Industry | Engineering & Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 960.5M | 909.1M |
| IPO Year | 2014 | 2018 |
| Metric | LMB | MGTX |
|---|---|---|
| Price | $81.26 | $12.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $116.67 | $24.57 |
| AVG Volume (30 Days) | 261.1K | ★ 780.8K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.68 | ★ 33.02 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $646,804,000.00 | $81,391,000.00 |
| Revenue This Year | $15.96 | $141.38 |
| Revenue Next Year | $5.90 | N/A |
| P/E Ratio | $227.53 | ★ N/A |
| Revenue Growth | 24.68 | ★ 144.57 |
| 52 Week Low | $65.08 | $6.31 |
| 52 Week High | $154.04 | $12.28 |
| Indicator | LMB | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.33 | 69.21 |
| Support Level | $79.99 | $7.10 |
| Resistance Level | $85.46 | $11.85 |
| Average True Range (ATR) | 4.35 | 0.63 |
| MACD | 0.30 | 0.22 |
| Stochastic Oscillator | 52.88 | 83.63 |
Limbach Holdings Inc is a building systems solutions firm that designs, delivers, and maintains mechanical (heating, ventilation, and air conditioning), electrical, plumbing, and controls (MEPC) systems. The Company partners with owners and operators of facilities across healthcare, industrial and manufacturing, data centers, life sciences, higher education, and cultural and entertainment markets. It operates through two segments: Owner Direct Relationships (ODR), which generates maximum revenue and includes owner direct projects, maintenance, and service on MEPC systems; and General Contractor Relationships (GCR), which manages new construction or renovation projects involving MEPC systems awarded by general contractors or construction managers.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.